Cargando…
Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m(2))
Autores principales: | Kuhadiya, Nitesh D., Mahmood, Israa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077383/ https://www.ncbi.nlm.nih.gov/pubmed/33936685 http://dx.doi.org/10.1002/ccr3.4022 |
Ejemplares similares
-
Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report
por: Mahmood, Israa, et al.
Publicado: (2020) -
Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
por: Kitamura, Koichi, et al.
Publicado: (2020) -
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023) -
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021) -
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)